Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06376721
Other study ID # TREC2024-KY016
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date April 14, 2024
Est. completion date October 31, 2027

Study information

Verified date April 2024
Source Beijing Tongren Hospital
Contact Liang Wang, M.D.
Phone +861058268442
Email wangliangtrhos@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The patients diagnosed with relapsed/refractory or advanced NK/T-cell Lymphoma (r/r NKTCL) were selected as the research objects. To explore effective and safe treatment for advanced or r/r NKTCL, the combination of PI3K-δ inhibitor Linperlisib with PD-1 blockade Camrelizumab and anti-metabolic agent Pegaspargase was applied for the treatment.


Description:

This is a prospective, single-arm, single-center Ib/II clinical trial that included an initial safety run-in phase with safety monitoring before the main enrollment (expansion phase).The aim of phase Ib is to evaluate the recommended phase 2 dose and dose-limiting toxicity (DLT), and the aim of phase II study is to evaluate, for the first time, the safety and efficacy of the treatment of Linperlisib combined with PD-1 blockade Camrelizumab and Pegaspargase in patients diagnosed with advanced or r/r ENKTL, respectively.


Recruitment information / eligibility

Status Recruiting
Enrollment 43
Est. completion date October 31, 2027
Est. primary completion date October 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Histopathology and immunohistochemistry confirmed diagnosis of ENKTL according to WHO 2016 criteria. - refractory or relapsed after initial remission, or Ann-Arbor stage III-IV de novo patients - PET/CT or CT/MRI with at least one objectively evaluable lesion. - Expected to survive more than 3 months. - General status ECOG score 0-2 points. - The laboratory test within 1 week before enrollment meets the following conditions: Blood routine: WBC=3×10e9/L, PLT=75×10e9/L, ANC=1.5×10e9/L. sCR=1.5 mg/dL,GFR=50 ml/min. Liver function: ALT & AST=3 times the upper limit of normal, TBIL =2 times the upper limit of normal. Serum fibrinogen level=1.0 g/L. •Sign the informed consent form Exclusion Criteria: - Patients with CNS involvement, or with other neoplasm; - Patients has received PI3K inhibitor treatment before enrollment - Poor performance status, ECOG=2; - Patients in lactation or pregnancy; - Patients (male or female) have the possibility of childbirth but are unwilling or have not taken effective contraceptive measures; - Patients allergic to any of the study drugs; - Patients with active infection; - Patients with a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; - Patients with a history of interstitial pneumonia, non infectious pneumonia, or highly suspected interstitial pneumonia; - Patients with a history of neurological or psychiatric disorders, including epilepsy or dementia, in the past - According to the researcher's judgment, there are accompanying diseases that seriously endanger patient safety or affect patient completion of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Linperlisib
Linperlisib: Phase Ib, oral, 80 mg/d, QD; Phase II, oral, RP2D, QD.
Camrelizumab
Camrelizumab for Injection: 200 mg/d, intravenous drip for 30 min (not less than 20 min and not more than 60 min), administered on day 1 of each cycle, observed for 2 hours after infusion. Every 3 weeks is a dosing cycle. Cycle 2 and subsequent cycles of dosing may be administered up to 5 days before or after the day of the scheduled dosing; more than 3 days after the date of the scheduled dosing will be considered a delayed dosing.
Pegaspargase
Pegaspargase: 2500 IU/m2, intramuscular injection, divided into three places, administered on the first day of each cycle, observed 2 hours after injection for the occurrence of anaphylactic reaction, if there is no anaphylactic reaction before giving other test drugs. Every 3 weeks as a dosing cycle. Camrelizumab for Injection should not be applied on the same day as Dexamethasonee.
Dexamethasone
Dexamethasone, 20 mg/d, days 1-4. Camrelizumab for Injection should not be applied on the same day as Dexamethasonee.

Locations

Country Name City State
China Liang Wang Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Tongren Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Drug safety According to NCI CTCAE v5.0 up to 2 years after enrollment
Primary The best objective response rate(ORR) over 6 treatment cycles Overall response rate means sum of complete response rate and partial response rate Within 6 treatment cycles (each cycle is 21 days)
Secondary Objective Response Rate(ORR) Objective response rate means sum of complete response rate and partial response rate At the end of 2nd, 4th, 6th treatment cycles,respectively (each cycle is 21 days)
Secondary Complete Response (CR) CR was defined as complete remission evaluated using PET-CT scan or BM test At the end of 2nd, 4th, 6th treatment cycles,respectively (each cycle is 21 days)
Secondary Progression Free Survival (PFS) Progression free survival was defined as the period from the start of treatment to the date of confirmed disease progression or death from any cause. From date of enrollment until the date of progression or date of death from any cause, whichever came first, assesed up to 2 years.
Secondary Overall Survival (OS) Overall survival is defined as the time from the date of treatment to the date of death. From date of enrollment until the date of documented death from any cause or follow up, whichever came first, assesed up to 2 years.
Secondary Disease Control Rate(DCR) Disease control rate discribes the percentage of patients with advanced cancer whose therapeutic intervention has led to a complete response, partial response, or stable disease Up to 2 years after enrollment.
See also
  Status Clinical Trial Phase
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Recruiting NCT04620655 - RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL N/A
Not yet recruiting NCT06434467 - The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma Phase 3
Recruiting NCT04582487 - Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL N/A
Suspended NCT04828174 - Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies Phase 1
Not yet recruiting NCT05068401 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Recruiting NCT03558412 - A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma Phase 4
Recruiting NCT05576532 - Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia Phase 2
Withdrawn NCT04860817 - A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL Early Phase 1
Recruiting NCT04004637 - CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia Phase 1
Recruiting NCT06136364 - CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study Phase 1